“Dose-modified lenalidomide induces sustained hematological response in patients with intermediate to high risk myelodysplasia”, Mediterr J Hematol Infect Dis, vol. 2, no. 2, p. e2010012, May 2010, doi: 10.4084/mjhid.2010.012.